Scarica l'app Stockscreener
47.05
3.93%
1.78
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Will breakout in Avidity Biosciences Inc. lead to full recovery2025 Top Decliners & Daily Entry Point Alerts - Newser
Can momentum traders help lift Avidity Biosciences Inc.2025 Big Picture & High Win Rate Trade Alerts - Newser
Avidity Biosciences Inc. stock momentum explainedJuly 2025 PreEarnings & Consistent Profit Trading Strategies - Newser
Detecting price anomalies in Avidity Biosciences Inc. with AIJuly 2025 Analyst Calls & Daily Technical Stock Forecast Reports - Newser
Does Avidity Biosciences Inc. show high probability of reboundQuarterly Trade Report & Proven Capital Preservation Methods - Newser
Reversal indicators forming on Avidity Biosciences Inc. stockTrade Volume Report & Fast Momentum Stock Entry Tips - Newser
What high frequency data says about Avidity Biosciences Inc.2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - Newser
How to monitor Avidity Biosciences Inc. with trend dashboards2025 Market Outlook & High Yield Stock Recommendations - Newser
Avidity Biosciences' RNA Stock Surges 36% Amid Novartis Acquisition Rumors - AInvest
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? - Yahoo Finance
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants - Quantisnow
What technical models suggest about Avidity Biosciences Inc.’s comeback2025 Performance Recap & Advanced Swing Trade Entry Plans - Newser
How to integrate Avidity Biosciences Inc. into portfolio analysis toolsEarnings Risk Summary & Smart Swing Trading Alerts - Newser
What moving averages say about Avidity Biosciences Inc.Layoff News & Weekly Momentum Stock Picks - Newser
Applying sector rotation models to Avidity Biosciences Inc.July 2025 Spike Watch & Accurate Buy Signal Alerts - Newser
Is Avidity Biosciences Inc. a top pick in the sectorPortfolio Value Summary & Verified Short-Term Plans - theviewers.co.kr
Can swing trading help recover from Avidity Biosciences Inc. lossesPortfolio Value Summary & Weekly Watchlist of Top Performers - Newser
Analyzing recovery setups for Avidity Biosciences Inc. investorsQuarterly Earnings Report & Technical Pattern Recognition Alerts - Newser
Is Avidity Biosciences Inc. stock entering bullish territoryWeekly Investment Summary & Safe Capital Growth Tips - Newser
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium - MSN
Can Avidity Biosciences Inc. recover in the next quarterShort Setup & Verified Swing Trading Watchlists - Newser
Avidity Biosciences CMO Hughes Buys, Sells Shares at $10.16 and $46.4 - AInvest
Risk vs reward if holding onto Avidity Biosciences Inc.Analyst Downgrade & Weekly High Return Stock Forecasts - Newser
Avidity Biosciences Inc. stock trend forecastJuly 2025 Spike Watch & Daily Oversold Bounce Ideas - Newser
Avidity Bio Climbs on Report of Novartis Takeover - MSN
Is a relief rally coming for Avidity Biosciences Inc. holdersM&A Rumor & Safe Entry Trade Reports - Newser
Technical analysis overview for Avidity Biosciences Inc. stockJuly 2025 Retail & Verified Chart Pattern Trade Signals - Newser
Avidity Biosciences Inc. Charts Flash Early Recovery SignalsEarnings Overview Summary & Fast Gain Swing Trade Alerts - newsimpact.co.kr
Avidity Biosciences Inc. Earnings Report Breakdown: What Investors Should KnowMarket Trend Report & Weekly Top Stock Performers List - Newser
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin - Barchart.com
Momentum Indicator Shows Bearish Divergence in Avidity Biosciences Inc.July 2025 Technicals & Low Drawdown Momentum Trade Ideas - metal.it
Avidity Biosciences Q2 Earnings: Strong Progress and Financial Position - AInvest
Trend analysis for Avidity Biosciences Inc. this weekJuly 2025 Update & Fast Gain Stock Trading Tips - Newser
Price Floor Holding on Avidity Biosciences Inc. — Rebound PossibleWeekly Stock Analysis & Weekly Sector Rotation Insights - metal.it
What makes Avidity Biosciences Inc. stock price move sharplyJuly 2025 Weekly Recap & Accurate Entry/Exit Alerts - thegnnews.com
Avidity Biosciences Advances RNA Therapeutics with Strong Q2 - TipRanks
What indicators show strength in Avidity Biosciences Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - Newser
Avidity Biosciences (RNA) CHRO McCarthy sells $465k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences (RNA) CHRO McCarthy sells $465k in stock - Investing.com
Avidity Biosciences Executives Sell Shares Under Trading Plans - TradingView
Avidity Biosciences Executives Make Substantial Share Trades Amid Company News - AInvest
Avidity Biosciences’ SWOT analysis: RNA stock poised for growth in rare muscle disease market - Investing.com
Avidity Biosciences’ SWOT analysis: RNA stock poised for growth in rare muscle disease market By Investing.com - Investing.com South Africa
What makes Avidity Biosciences Inc. stock attractive to long term investors2025 EndofYear Setup & Verified Chart Pattern Signals - Newser
Avidity Biosciences Inc. Moves Into Overbought Range Analysts CautiousTrend Analysis for Safer Trades Gains Popularity - 선데이타임즈
Avidity Biosciences RNA 2025Q2 Earnings Preview Upside Potential on Novartis Acquisition Talks - AInvest
Avidity Biosciences Bets Big On Rare Disease Therapies - Finimize
Avidity Biosciences' Promising Pipeline: Buy Rating Maintained by Ananda Ghosh - AInvest
Avidity Biosciences Maintains Strong Buy Rating With $75 Price Target - AInvest
Avidity Biosciences Q2 Results: Analysts Boost Revenue Forecasts, Raise Loss Per Share Estimates - AInvest
The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal - MSN
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78 - 富途牛牛
0.95%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):